MYOCARDIAL PERFUSION ASSESSMENT IN FORECASTING EFFECT OF CORONARY ANGIOPLASTY IN PATIENTS WITH ISCHEMIC CHRONIC HEART FAILURE

Aim. To define influence of the left ventricle (LV) perfusion defects on the clinical status dynamics after coronary angioplasty in patients with the expressed myocardium dysfunction of ischemic etiology. Materials and methods. Examined 86 patients (81 men and 5 women aged from 46 to 73 years) before and in 2–3 days after percutaneous coronary intervention with diagnosis: CAD, CHF with NYHA class III–IV, echocardiography parameters of LV: ejection fraction less than 40%, end-diastolic volume is more than 200 ml. Perfusion defects of myocardium estimated with use of ECG-gated single photon emission computed tomography. Predictors were defined: perfusion defects on LV apex (in score), perfusion defects in the area of LAD, LCx and RCA (%), the LV global perfusion defects (in score and %). Results. In 42% of cases 6-minute walk test increased to 3 times; The NYHA class decreased by 2 classes (group 1). In 28 cases 6-minute walk test increased to 2 times and the NYHA class decreased on 1 class. In 22 patients 6-minute walk test increased less than 50% of reference values and there was no dynamics NYHA class (50 patients of the group 2). Initial extent of LV global perfusion defects in group 1 – 41,2 ± 4,0%, in group 2 – 58,3 ± 2,4% (р = 0,0004). Similar values are received for perfusion indicators in the area of LAD and the LV apex. Prevalence of myocardial perfusion defects at rest reflects prevalence of a cardiosclerosis in a cardiac muscle. Conclusion. Degree of LV myocardial perfusion defects in patients with the expressed heart failure of ischemic etiology is the key indicator influencing clinical efficiency of coronary angioplasty. Critical size for definition of the favorable forecast of revascularization are 60% and more perfusion defects testifying that in a cardiac muscle the focal cardiosclerosis prevails over the functioning myocardium. 

1. Kunadian V, Pugh A, Zaman AG, Qiu W. Percutaneous coronary intervention among patients with left ventricular systolic dysfunction: a review and meta-analysis of 19 clinical studies. Coron Artery Dis. 2012 Nov; 23 (7): 469–479.

2. Бокерия ЛА, Алекян БГ, Абросимов АВ, Айвазян ГГ. Чрескожные коронарные вмешательства у больных с дисфункцией левого желудочка (фракция выброса меньше или равна 30%). Грудная и сердечно-сосудистая хирургия. 2013; 6: 10–19. Bokeriya LA, Alekyan BG, Abrosimov AV, Ayvazyan GG. Chreskozhnye koronarnye vmeshatel'stva u bol'nyh s disfunkciey levogo zheludochka (frakciya vybrosa men'she ili ravna 30%). Grudnaya i serdechno-sosudistaya hirurgiya. 2013; 6: 10–19.

3. Шашкова НВ, Терещенко СН, Самойленко ЛЕ. Влияние ангиопластики на клиническое течение заболевания, перфузию и сократительную способность миокарда у больных с хронической сердечной недостаточностью ишемической этиологии. Кардиoлогия. 2014; 4 (54): 21–28. Shashkova NV, Tereshchenko SN, Samoylenko LE. Vliyanie angioplastiki na klinicheskoe techenie zabolevaniya, perfuziyu i sokratitel'nuyu sposobnost' miokarda u bol'nyh s hronicheskoy serdechnoy nedostatochnost'yu ishemicheskoy ehtiologii. Kardiologiya. 2014; 4 (54): 21–28.

4. Marui A, Kimura T, Nishiwaki N, Komiya T, Hanyu M, Shiomi H et al. CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Three-year outcomes after percutaneous coronary intervention and coronary artery bypass grafting in patients with heart failure: from the CREDOKyoto percutaneous coronary intervention/coronary artery bypass graft registry cohort-2†. Eur. J. Cardiothorac Surg. 2015 Feb; 47 (2): 316–321. doi: 10.1093/ejcts/ ezu131. Epub 2014 Mar 23.

5. Buszman P, Szkróbka I, Tendera Z, Gruszka1 A, Bialkowska B, Parma R et al. Early and late results of percutaneous revascularization in patients with ischemic cardiomyopathy and decreased left ventricular ejection fraction. (Revascularisation in Heart Failure Trial, REHEAT Registry). EuroInterv. 2005; 1: 186–192.

6. Программа обработки кардиологических функциональных исследований (ИНДИС-КАРФИ). Свидетельство о госрегистрации программы для ЭВМ No 2014662434, 28.11.2014 г. Programma obrabotki kardiologicheskih funkcional'nyh issledovaniy (INDIS-KARFI). Svidetel'stvo o gosregistracii programmy dlya EHVM No 2014662434, 28.11.2014 g.

7. Gould KL. Focus for the new millennium – diffuse coronary artery disease and new paradigms in cardiovascular medicine. ACC Curr. J. Review. 2000; 9: 10–16.

8. Gerber BL, Rousseau MF, Ahn SA, le Polain de Waroux JB, Pouleur AC, Phlips T et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. Am. Coll. Cardiol. 2012 Feb 28; 59 (9): 825–835. doi: 10.1016/j.jacc.2011.09.073

9. Rizzello V, Schinkel AF, Bax JJ et al. Individual prediction of functional recovery after coronary revascularization in patients with ischemic cardiomyopathy: the scarto-biphasic model. Am. J. Cardiol. 2003 Jun 15; 91 (12): 1406–1409.

10. Schinkel AF, Valkema R, Geleijnse ML, Sijbrands EJ, Poldermans D. Single-photon emission computed tomography for assessment of myocardial viability. EuroIntervention. 2010 May; 6 Suppl G: 115–122. doi: 10.4244/.

11. Samady H, Elefteriades JA, Abbott BG et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation. 1999; 100: 1298–304.